INO. 10/10/12 Inovio Pharmaceuticals' Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells -- Article in Peer-Reviewed Science-Translational Medicine Reports Strong and Durable T Cell Responses from VGX-3100, Which is Designed to Treat Cervical Dysplasias Caused by HPV Infection -- On-going phase II efficacy study will determine vaccine's ability to reverse disease progression to cervical cancer http://ih.advfn.com/p.php?pid=nmona&article=54469478